Prediction of cancer-associated venous thromboembolism

Venous thromboembolism (VTE) is a common complication in patients with cancer, leading to increased mortality and morbidity, decreased quality of life and higher healthcare costs. Primary thromboprophylaxis with low molecular weight heparin (LMWH) has been shown to be efficacious in preventing VTE, reducing the risk with 46%. However, current international guidelines do not recommend routine prophylactic anticoagulant therapy in ambulatory cancer patients due to an unfavorable risk-benefit ratio. Risk stratification tools using clinical and laboratory variables have been developed to help predict which patients will develop cancer-associated VTE. However, external validation of these tools remain needed before clinical implementation can be justified. The main objective of this study is to evaluate and compare the performance several risk scores, including the Khorana, PROTECHT and CONKO and TIC-ONCO score. In addition, the additive value of other clinical risk factors and genetic mutations will be evaluated.
We aim to enroll all CPCT-02 study (clinicaltrials.gov identifier: NCT01855477) participants in a retrospective cohort study. Enrollment of at least thousand patients is intended in order to observe around 50-80 events to provide sufficient statistical power.

VTE risk prediction might be improved by using the modified risk scores.

6 months from entry time, 12 months from entry time, and longer follow-up periods.